Abstract
The c-Met/HGF pathway is implicated in cancer progression and dissemination. Many inhibitors have been developed to target this pathway. Unfortunately, most trials have failed to demonstrate efficacy. However, clinical trials have not adequately tested the concept of c-Met pathway inhibition due to the lack of appropriate patient selection criteria.
Keywords:
c-Met; cancer; clinical trials; inhibitor.
Copyright © 2017 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Clinical Trials as Topic
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Protein Kinase Inhibitors / therapeutic use*
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Protein Kinase Inhibitors
-
MET protein, human
-
Proto-Oncogene Proteins c-met